Evidence-based medicine: Empiric antibiotic therapy in community-acquired pneumonia

Journal of Infection

Volumn 39, Issue 3, 1999, Pages 171-178

  Read, Robert C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; PENICILLIN RESISTANCE; PNEUMONIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0033383958     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(99)90043-9     Document Type: Review

References (59)

1. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. Prognosis and outcome of patients with community-acquired pneumonia. JAMA 1996; 275: 134-141.
2. Tillet WS, Cambier MJ, McCormack JE. The treatment of lobar pneumonia and pneumococcal empyema with penicillin. Bull NY Acad Med 1944; 20: 142-178.
3. Woodhead MA, McFarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1: 671-674.
4. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcome in elderly patients with pneumonia. JAMA 1997; 278: 2080-2084.
5. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Lobo E, Rodriguez-Roisin R. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Resp Dis 1991; 144: 312-318.
6. Bartlett JG, Breiman RS, Mandell LA, File TN. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-838.
7. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-350.
8. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Resp Dis 1993; 148: 1418-1426.
9. ERS Taskforce Report. Guidelines for the management of adults with community-acquired lower respiratory tract infections. Eur Resp J 1998; 11: 986-991.
10. Douglas-Campbell G, Silberman R. Drug-resistant S pneumoniae Clin Infect Dis 1998; 26: 1188-1195.
11. Goldsmith CE, Moore JE, Murphy PG. Pneumococcal resistance in the U.K. J Antimicrob Chemother 1997; 40(Suppl. A): 11-18.
12. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl Med 1995; 333: 474-480.
13. Johnson AP, Livermore DM, Woodford N et al. High level β-lactam resistance in strains of Streptococcus pneumoniae isolated in the U.K. J Antimicrob Chemother. 1998; 42: 115-116.
14. Wallace RJ, Martin RR, Quinones FJ, Greenberg SB. Ceforanide and cefazolin therapy for pneumonia: comparative clinical trial. Antimicrob Agents Chemother 1981; 2: 648-652.
15. Wallace RJ, Neifield SL, Waters S, Waters B, Awe RJ, Wiss K, Martin RR, Greenberg SB. Comparative trial of cefonicids and cefamandole in the therapy of community-acquired pneumonia. Antimicrob Agents Chemother 1982; 21: 231-235.
16. Blaser MJ, Klaus BD, Jacobson JA, Kasworm E, La Force FM. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. Antimicrob Agents Chemother 1983; 24: 163-167.
17. Weber DJ, Calderwood SB, Karchmer AW, Pennington JE. Ampicillin v. cefamandil as initial therapy for community-acquired pneumonia. Antimicrob Agents Chemother 1987; 31: 876-882.
18. Zuck P, Reo Y, Ichou FJ. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother. 1990; 26(Suppl. E): 71-77.
19. Williams D, Perri M, Zervos MJ. Randomised comparative trial with ampicillin/sulbactam v. cefamandole in the therapy of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13: 293-298.
20. De Palma M, Rocchi D, Canepa G, Peri A, Cantone V. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open label, controlled, randomised study. The Italian Multi-centre Community-acquired Pneumonia Group. Clin Therapeut 1995; 17: 413-424.
21. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuoroxime axetil and oral amoxycillin/clavulanatc in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1996; 37: 555-564.
22. Oh HM, Kg AW, Lee SK. Cefuroxime compared to amoxycillin/clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J 1996; 376: 255-257.
23. Ho A, Leung R, Lai CK, Chan TH, Chan CH. Hospitalised patients with community-acquired pneumonia in Hong Kong. A randomised study comparing imipenem/cilastin and ceftazidime. Respiration 1997; 64: 224-228.
24. Drehobl M, Bianchi P, Keyserling CH, Tack KJ, Griffin TJ. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1579-1583.
25. Zervos M, Nelson M. Cefepime v. ceftriaxone for empiric treatment of hospitalised patients with community-acquired pneumonia. The Cefepime Study Group Antimicrob Agents Chemother. 1998; 42: 729-733.
26. Poirier R. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1991; 27(Suppl. A): 109-116.
27. Anderson G, Esmond TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stereate in community-acquired pneumonia. J Antimicrob Chemother. 1991; 27(Suppl. A): 117-124.
28. Chien SM, Pichotta P, Seipman N, Chan CK. Treatment of community-acquired pneumonia. A multi-centre, double-blind, randomised study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993; 103: 697-701.
29. Liippo K, Tala E, Puolijoki H, Bruckner OJ, Rodrig J, Smits JP. A comparative study of clarithromycin and erythromycin in bacterial pneumonia. J Infect. 1994; 28: 131-139.
30. Block S, Hedrick HJ, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumonias in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14: 471-477.
31. Rizzato G, Montemerro L, Fraioli P, Montanari G, Fanti D, Bozzoli R, Magliano E. Efficacy of a three-day course of azithromycin in a moderately severe community-acquired pneumonia. Eur Resp J 1995; 8: 398-402.
32. Jang TN, Liu CY, Wang FT, Yang SP, Fung CB. A randomised comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia. Chung-Hua-1-Hseuh-Tsa-Chi-Taipei 1995; 55: 302-306.
33. Roord JJ, Wolf BH, Gossens MM, Kimpen JL. Prospective open randomised study comparing efficacies and safeties of a three-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired lower respiratory tract infections. Antimicrob Agents Chemother. 1996; 40: 2765-2768.
34. Genne D, Seigrist HH, Humair L, Janin-Jaquat B, de-Torrente A. Clarithromycin v. amoxycillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Microbiol Infect Dis. 1997; 16: 783-788.
35. Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998; 41(Suppl. B): 75-80.
36. O'Doherty Muller O. Randomized multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17: 828-833.
37. Mouton I, Beuscart C, Leroy O, Ajana F, Charrel J. Evaluation of ciprofloxacin v. amoxycillin and clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia. Pathol Biol Paraes 1991; 39: 34-37.
38. Gaillat J, Bru JP, Sedallian A. Penicillin G/ofloxacin v. erythromycin/ amoxycillin-clavulanatein the treatment of severe community/ acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13: 639-644.
39. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G. Treatment of community-acquired pneumonia: a randomised comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Resp J 1995; 8: 1999-2007.
40. Ortqvist A, Valtonen M, Carrs O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia. A multi-centre, double-blind, randomised study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 1996; 110: 1499-506.
41. Plouffe JF, Herbert M, File TM, Baird I, Parson JN, Kahn JB, Rielly-Gauvin KT. Ofloxacin v. standard therapy in treatment of community-acquired pneumonia requiring hospitalisation. Pneumonia Study Group. Antimicrob Agents Chemother 1996; 40: 1175-1179.
42. Portier H, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. J Antimicrob Chemother 1996; 37(Suppl. A): 83-91.
43. Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, Talbot GH. Sparfloxacin v cefaclor in the treatment of patients with community-acquired pneumonia. A randomised, double-masked, comparative multi-centre study. Clinical Therapeutics 1997; 19: 936-953.
44. O'Docherty B, Dutchman DA, Pettit R, Maroli A. Randomised, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40(Suppl. A): 73-81.
45. Ragnar-Norrby S. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother 1997; 39: 499-508.
46. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multi-centre randomised study comparing the efficacy and safety of intravenous and oral levofloxacin v. ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-1972.
47. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21: 103-112.
48. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397-404.
49. Tremolieres R, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high dose amoxicillin (lg tds) in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 447-453.
50. Aubres M, Verster R, Regamey C, Geslin P, Vercken JB. Once daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26: 1312-1320.
51. Calderon E, Gatica R, Echaniz G, Conde C, Salinas L, Olvera G, Zorrilla E, Velazquez ME. Treatment of presumed bacterial pneumonia in ambulatory children. Clin Ther 1991; 13: 699-706.
52. Mulholland EK, Falade AG, Corrah BT, Omosigho C, N'Jai P, Giadom B, Adegbola RA, Tschappler H, Todd J, Greenwood BM. A randomised trial of chloramphenicol v. trimethoprim-sulfamethoxazole for the treatment of malnourished children with community-acquired pneumonia. Paed Infec Dis J 1995; 14: 959-965.
53. Ailani RK, Agastya G, Ailani R, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999; 159:266-270.
54. Gleason BB, Kapoor WM, Strone RA, Lave JR, Obrowsky DS, et al. Medical outcomes and antimicrobial costs for the use of the American Thoracic Society Guidelines for out-patients with community-acquired pneumonia. JAMA 1997; 278: 32-39.
55. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Eng J Med 1997; 336: 243-250.
56. Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Bernan DC et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as out-patients. Arch Intern Med 1998; 158: 1350-1356.
57. Farr BM, Sloman AJ, Frisch MJ. Predicting death in patients hospitalised for community-acquired pneumonia. Ann Intern Med 1991; 115: 428-436.
58. Karalus NC, Cursons MT et al. Community-acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46: 413-418.
59. Ewig S, Ruiz M, Menser J, Marcos MA, Martinez JA et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Resp Crit Care Med 1998; 158: 1102-1108.